| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
Antipsychotic agentsTranquilizerSchizophrenia| 1 | 1999 | Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998. | 
| + | - | nl | Schizophr Bull 25(2):395-405 (1999) |
| 2 | 1997 | Neuroleptic intolerance. |
| + | - | nl | Schizophr Bull 23(4):567-82 (1997) |
| 3 | 1996 | Medical complications of new antipsychotic drugs. |
| + | - | nl | Schizophr Bull 22(3):475-83 (1996) |
| 4 | 1995 | Reevaluation of the mesolimbic hypothesis of antipsychotic drug action. |
| + | - | nl | Schizophr Bull 21(1):67-74 (1995) |
| 5 | 1991 | New antipsychotics: classification, efficacy, and adverse effects. |
| + | - | nl | Schizophr Bull 17(2):289-309 (1991) |
| 6 | 1991 | The mechanism of action of novel antipsychotic drugs. |
| + | - | nl | Schizophr Bull 17(2):263-87 (1991) |
| 7 | 2005 | The dosing of atypical antipsychotics. |
| + | - | nl | Psychosomatics 46(3):262-73 (2005) de Leon J |
| 8 | 2007 | Atypical antipsychotics: new drugs, new challenges. |
| + | - | nl | Cleve Clin J Med 74(8):597-606 (2007) Mathews M |
| 9 | 1981 | Current theories about the mechanisms of benzodiazepines and neuroleptic drugs. |
| + | - | nl | Anesthesiology 54(1):66-72 (1981) |
| 10 | 2007 | Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. |
| + | - | nl | Br J Psychiatry 191():238-45 (2007) Rosenheck RA |
| 11 | 2004 | Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. |
| + | - | nl | Am J Psychiatry 161(3):414-25 (2004) Correll CU |
| 12 | 2005 | Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. |
| + | - | nl | Can J Psychiatry 50(9):541-7 (2005) Margolese HC |
| 13 | 2005 | Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. |
| + | - | nl | Can J Psychiatry 50(11):703-14 (2005) Margolese HC |
| 14 | 2002 | Atypical antipsychotics: mechanism of action. |
| + | - | nl | Can J Psychiatry 47(1):27-38 (2002) |
| 15 | 2005 | Atypicality of atypical antipsychotics. |
| + | - | nl | Prim Care Companion J Clin Psychiatry 7(6):268-74 (2005) Farah A |
| 16 | 2003 | A meta-analysis of the efficacy of second-generation antipsychotics. |
| + | - | nl | Arch Gen Psychiatry 60(6):553-64 (2003) Davis JM |
| 17 | 2004 | Off-label indications for atypical antipsychotics: A systematic review. |
| + | - | nl | Ann Gen Hosp Psychiatry 3(1):4 (2004) Fountoulakis KN |
| 18 | 2008 | Effectiveness of second generation antipsychotics: a systematic review of randomized trials. |
| + | - | nl | BMC Psychiatry 8():31 (2008) Johnsen E |
| 19 | 2010 | First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. |
| + | - | nl | J Can Acad Child Adolesc Psychiatry 19(2):124-37 (2010) Panagiotopoulos C |
| 20 | 1999 | The role of serotonin in antipsychotic drug action. |
| + | - | nl | Neuropsychopharmacology 21(2 Suppl):106S-115S (1999) |
| 21 | 2008 | Dosing atypical antipsychotics. |
| + | - | nl | CNS Spectr 13(5 Suppl 9):1-16 (2008) Cutler A |
| 22 | 2007 | Acute and long-term adverse effects of antipsychotics. |
| + | - | nl | CNS Spectr 12(12 Suppl 21):10-4 (2007) Correll CU |
| 23 | 2007 | Drug-drug interactions with antipsychotics. |
| + | - | nl | CNS Spectr 12(12 Suppl 21):6-9 (2007) Meyer J |
| 24 | 2007 | Balancing efficacy and safety in treatment with antipsychotics. |
| + | - | nl | CNS Spectr 12(10 Suppl 17):12-20, 35 (2007) Correll CU |
| 25 | 1999 | The use of atypical antipsychotics in the management of schizophrenia. |
| + | - | nl | Br J Clin Pharmacol 47(1):13-22 (1999) |
| 26 | 2007 | Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. |
| + | - | nl | J Pharmacol Exp Ther 320(3):961-8 (2007) Terry AV Jr |
| 27 | 2008 | Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. |
| + | - | nl | Pharmacol Rev 60(3):358-403 (2008) Lieberman JA |
| 28 | 2001 | Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. |
| + | - | nl | Pharmacol Rev 53(1):119-33 (2001) |
| 29 | 2002 | What's in a name? The evolution of the nomenclature of antipsychotic drugs. |
| + | - | nl | J Psychiatry Neurosci 27(3):168-75 (2002) |
| 30 | 2001 | How do the atypical antipsychotics work? |
| + | - | nl | J Psychiatry Neurosci 26(5):385-94 (2001) |
| 31 | 2000 | Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. |
| + | - | nl | J Psychiatry Neurosci 25(2):137-53 (2000) Stip E |
| 32 | 1999 | Conventional versus novel antipsychotics: changing concepts and clinical implications. |
| + | - | nl | J Psychiatry Neurosci 24(5):431-41 (1999) |
| 33 | 2005 | Modern antipsychotic drugs: a critical overview. |
| + | - | nl | CMAJ 172(13):1703-11 (2005) Gardner DM |
| 34 | 2005 | Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. |
| + | - | nl | JAMA 294(15):1934-43 (2005) |
